Information Provided By: 
Fly News Breaks for May 6, 2016
ENDP
May 6, 2016 | 07:35 EDT
UBS lowered its price target on Endo to $30 from $56 citing the company's report of much worse than expected results its disappointing cash flow situation, and the difficult market and pharma sector environment. Sales guidance was reduced due to the shortfall in generics and the delay of products, the firm noted. UBS maintained its Buy rating on Endo shares based on the expectation for a return to growth in 2017.
News For ENDP From the Last 2 Days
There are no results for your query ENDP
